Cargando…

Multigene Expression Signatures in Early Hormone Receptor Positive HER 2 Negative Breast Cancer

BACKGROUND: The standard treatment of hormone receptor positive, HER2 negative early breast cancer (BC) is surgery followed by adjuvant systemic therapy either with endocrine therapy alone or with the addition of chemotherapy followed by endocrine therapy. Adjuvant systemic therapy reduces the risk...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ovcaricek, Tanja, Takac, Iztok, Matos, Erika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sciendo 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6765159/ https://www.ncbi.nlm.nih.gov/pubmed/31553709 http://dx.doi.org/10.2478/raon-2019-0038

Ejemplares similares

Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative
por: Giorgi Rossi, Paolo, et al.
Publicado: (2021)

A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer
por: Yau, Christina, et al.
Publicado: (2010)

Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patients
por: Dovnik, Nina Fokter, et al.
Publicado: (2016)

EndoPredict(®) in early hormone receptor-positive, HER2-negative breast cancer
por: Almstedt, K., et al.
Publicado: (2020)

Triple negative breast cancer – prognostic factors and survival
por: Ovcaricek, Tanja, et al.
Publicado: (2010)

Clinical Implications of Androgen-Positive Triple-Negative Breast Cancer
por: Brumec, Maša, et al.
Publicado: (2021)

Breast Cancer During Pregnancy: Retrospective Institutional Case Series
por: Matos, Erika, et al.
Publicado: (2021)

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER(+), HER2(−) early breast cancer
por: Exner, R, et al.
Publicado: (2014)

The multigene classifiers 95GC/42GC/155GC for precision medicine in ER‐positive HER2‐negative early breast cancer
por: Naoi, Yasuto, et al.
Publicado: (2021)

Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer
por: Gong, Chang, et al.
Publicado: (2016)

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019)

First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer
por: Ettl, Johannes, et al.
Publicado: (2020)

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare
por: Müller, Volkmar, et al.
Publicado: (2023)

Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer
por: Mutai, Raz, et al.
Publicado: (2021)

Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
por: Yang, Jiangping, et al.
Publicado: (2020)

Hormone Receptor–Positive, HER2-Negative Breast Cancer: Recent Advances and Best Practices
por: Schwartzberg, Lee, et al.
Publicado: (2020)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2021)

Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
por: Andrahennadi, Samitha, et al.
Publicado: (2021)

Establishment and validation of a multigene model to predict the risk of relapse in hormone receptor-positive early-stage Chinese breast cancer patients
por: Liu, Jiaxiang, et al.
Publicado: (2023)

PROCURE European consensus on breast cancer multigene signatures in early breast cancer management
por: Curigliano, Giuseppe, et al.
Publicado: (2023)

Should a Multigene Signature be Used in all Luminal Early Breast Cancers
por: Hajjaji, Nawale, et al.
Publicado: (2019)

Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer
por: Lu, Ming, et al.
Publicado: (2010)

Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
por: Vos, Hanne, et al.
Publicado: (2021)

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Ballinger, Tarah J., et al.
Publicado: (2018)

Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features
por: Benefield, Halei C, et al.
Publicado: (2020)

Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection
por: Parati, Maria Chiara, et al.
Publicado: (2022)

Predicting the Response of Neoadjuvant Chemotherapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer With Axillary Lymph Node Metastasis by Multigene Assay
por: Lee, Jun-Hee, et al.
Publicado: (2022)

Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review
por: Garutti, Mattia, et al.
Publicado: (2022)

Advances in Tumour-Infiltrating Lymphocytes for Triple-Negative Breast Cancer Management
por: Gorenšek, Rok, et al.
Publicado: (2023)

CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
por: Matutino, Adriana, et al.
Publicado: (2018)

Hormone Receptor Positive/HER2 Negative Breast Cancer With Isolated Bladder Metastasis: A Rare Case
por: Khan, Noman Ahmed Jang, et al.
Publicado: (2021)

Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer
por: Torrisi, Rosalba, et al.
Publicado: (2022)

ADAM8 is expressed widely in breast cancer and predicts poor outcome in hormone receptor positive, HER-2 negative patients
por: Pianetti, Stefania, et al.
Publicado: (2023)

A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer
por: Sparano, Joseph A., et al.
Publicado: (2017)

Efficacy of an RNA-based multigene assay with core needle biopsy samples for risk evaluation in hormone-positive early breast cancer
por: Lee, Jeeyeon, et al.
Publicado: (2019)

Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer
por: Alshamsan, Bader, et al.
Publicado: (2021)

Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma
por: Rossi, L, et al.
Publicado: (2015)

MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer
por: Han, Jinil, et al.
Publicado: (2017)

Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation
por: Schwartzberg, Lee S., et al.
Publicado: (2021)

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
por: Migliaccio, Ilenia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3rp8ir5od7hq20u5r62qbqkn9f